RxDoctor Payments Data

Miguel Campos Esteve, MD

Interventional Cardiology · San Juan, PRNPI 1578548582

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (57.1%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by Abbott at 36.0% of the total. That places this record below the midpoint for interventional cardiology clinicians in PR, where the typical reported total is $12,032.

$7,865in general payments, 2019–2025

Across 258 payments — averaging $30.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$3K
  • Medtronic$1K
  • Edwards Lifesciences$1K
  • Boston Scientific$1K
  • Amgen$338
  • Johnson & Johnson$301
  • plus $813 from 9 others

What the payments were for

  • Consulting fees$2,30029%
  • Travel & lodging$99813%
  • Food & beverage$4,49357%
  • Gifts$751%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,865 in reported general payments places this provider in the 35th percentile of 39 interventional cardiology providers in Puerto Rico.

See all interventional cardiology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$29,875
Medicare patients
46
Services billed
194

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BrilintaTicagrelor39$17,419
Nitroglycerin107$1,433
ClopidogrelClopidogrel Bisulfate149$1,271
Metoprolol Succinate93$801
Ranolazine ErRanolazine12$675
Atorvastatin Calcium76$595
Amlodipine Besylate50$259
Isosorbide Mononitrate ErIsosorbide Mononitrate20$121
Spironolactone13$117
Rosuvastatin Calcium13$112
Losartan Potassium15$102
Furosemide11$49

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBrilinta$125$17,41939 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 39 interventional cardiology providers in Puerto Rico.

Other interventional cardiology in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →